<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434681</url>
  </required_header>
  <id_info>
    <org_study_id>PARAC_L_00859</org_study_id>
    <nct_id>NCT00434681</nct_id>
  </id_info>
  <brief_title>Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.</brief_title>
  <official_title>Multicentre, Open, Non-Comparative Study of the Acceptability and Safety of Paracetamol Oral Paediatric Suspension at 4.8%.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the acceptability over 24 hours of a new paracetamol formulation 4.8% paediatric
      oral suspension in children weighing between 3 and 26 kg including limits
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability data: Overall evaluation of the treatment by the child's parents or the minder, measured using a semi-quantitative scale with 4 levels (very acceptable, acceptable, indifferent, refusal), for 24 hours (4 evaluations at 6 hour intervals).</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety data : Events reported by the child, parents or legal guardian during visit 2 ; events compiled in the child's diary ; events recorded by the investigator during Visit 2</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability data: Overall evaluation of the child (from 3 years), using a Hedonic Visual Scale during the last administration prior to Visit V2.</measure>
  </secondary_outcome>
  <enrollment>48</enrollment>
  <condition>Fever</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol 4.8% paediatric oral suspension</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following information on clinical trials is provided for information purposes only to
        allow patients and physicians to have an initial discussion about the trial. This
        information is not intended to be complete information about the trial, to contain all
        considerations that may be relevant to potential participation in the trial, or to replace
        the advice of a personal physician or health professional.

        Main criteria are listed hereafter :

        Inclusion Criteria:

          -  Children of both sexes weighing between 3 and 26 kg including limits.

          -  With a fever and/or painful episode justifying a paracetamol treatment for a minimum
             duration of 24 hours.

          -  Likely to be followed throughout the entire study period in out-patient.

          -  For whom the informed consent has been signed by the parents or legal guardian and by
             the child if old enough (see chapter 12.3).

        Exclusion Criteria:

          -  Presenting digestive disorders, vomiting.

          -  Presenting a hypersensitivity to paracetamol or one of the ingredients of the study
             product

          -  Presenting a hepatocellular failure.

          -  Presenting a fructose intolerance.

          -  Presenting a serious concomitant disease, such as cancer, immune deficiency or a
             serious renal, hepatic cardiac, neurological, psychiatric or metabolic disease.

          -  Presenting a history of significant biological anomalies.

          -  Treated with KayexalateÂ® (sodium polystyrene sulphonate)

          -  Not covered by a social security regime.

          -  Whose parents are incapable of understanding

          -  Who cannot come back to the consultation for the final evaluation and/or submit to the
             study constraints.

          -  Who participated in another clinical study in the 30 days prior to inclusion.

          -  Is a relation of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique COUDERC, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2007</study_first_posted>
  <last_update_submitted>July 18, 2008</last_update_submitted>
  <last_update_submitted_qc>July 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2008</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

